Insilico Medicine Inc. has identified new glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of atherosclerosis, coronary heart diseases, dementia, diabetes, hypertension, obesity, hyperlipidemia and cerebral infarction.
Haisco Pharmaceutical Group Co. Ltd. has synthesized new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of inflammatory bowel disease and psoriasis.
Augustine Therapeutics NV has divulged thiomethyl carbonyl compounds acting as histone deacetylase 6 (HDAC6) and/or HDAC1 and/or HDAC3 inhibitors. They are reported to be useful for the treatment of inflammatory disorders, autoimmune disease, cancer, neurodegeneration, pain, neuropathy, psychiatric and cardiovascular disorders.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly patented new potassium voltage-gated channel subfamily A member 3 (KCNA3; Kv1.3) blockers for use in the treatment of autoimmune diseases.
Asieris Pharmaceuticals Co. Ltd. and Shanghai Yahong Meditech Co. Ltd. have discovered new poly(ADP-ribose) glycohydrolase (PARG) inhibitors potentially useful for the treatment of cancer.
Researchers from Jiangsu Ocean University reported the synthesis and preclinical evaluation of novel derivatives of SKF-83566, a selective D1 receptor antagonist widely used in dopamine signaling research.
Tessera Therapeutics Inc.’s lead in vivo gene editing program, TSRA-196, has been awarded orphan drug and fast track designations by the FDA for adults with α-1 antitrypsin deficiency (AATD).
Researchers from Shanghai Ailux Biotechnology Co. Ltd. have disclosed preclinical data regarding their humanized bispecific antibody ALX-001 targeting TL1A and IL-23 for the potential treatment of immune-mediated inflammatory diseases (IMIDs).
Angelini Pharma SpA and Quiver Bioscience Inc. have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. Under the multiyear collaboration, Angelini Pharma will leverage Quiver’s technology platform to gain deeper understanding of a broad set of developmental and epileptic encephalopathies.
Centauri Therapeutics Ltd. has extended its series A financing round to £30 million (US$40.5 million) with the addition of a new £6 million (US$8 million) investment. Centauri initially closed its £24 million (US$32 million) series A round in 2022.
RSS
